Sanctura XR to begin Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Indevus is on track to initiate a Phase III program for its once-daily Sanctura (trospium) formulation Sanctura XR this summer, "with a goal of submitting an NDA in the second half of next year," the firm announces June 15. Esprit Pharma is Indevus' new co-promotion partner for the Sanctura overactive bladder therapy brand under a July 1 deal; Pliva had been Indevus' previous marketing partner...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.